ScreenerHero

TLX Telix Pharmaceuticals Limited

NAS · US · Healthcare · Biotechnology · telixpharma.com
11.12USD+3.15%Mkt Cap: 3.77B $P/E: 111.20

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segment…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.77B USD
Enterprise Value3.99B USD
Revenue (TTM)890.79M USD
Gross Profit426.44M USD
Net Income (TTM)-7.13M USD
Revenue/Share2.61 USD
Last Price11.12 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)111.20
P/E (Forward)-401.91
PEG—
EV/EBITDA57.17
EV/Revenue4.48
P/S4.10
P/B8.79
EPS (TTM)0.10
EPS (Forward)-0.03
52W Range
6.28074% of range12.80
52W High12.80 USD
52W Low6.280 USD
Profitability
Gross Margin53.05%
Oper. Margin9.71%
EBITDA Margin7.84%
Profit Margin-0.89%
ROE-1.72%
ROA-0.61%
Growth
Revenue Growth22.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.01M USD
CapEx (TTM)43.78M USD
FCF Margin-7.03%
FCF Yield-1.66%
Net Debt327.95M USD
Net Debt/EBITDA4.70
Balance Sheet
Debt/Equity1.12
Current Ratio2.01
Quick Ratio1.74
Book Value/Sh1.23 USD
Cash/Share0.74 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.45 USD
Upside (mean)+83.9%
Target Range18.03 USD – 22.19 USD
18.03+83.9% to mean22.19
# Analysts4
Ownership
Shares Out.338.78M
Float273.61M
Insiders0.00%
Institutions0.98%
Short Interest
Short Ratio1.3d
Short % Float0.11%
Short % Out.0.10%
Shares Short352.52K
Short (prev mo.)244.90K
Technical
SMA 5011.38 (-2.3%)
SMA 2009.665 (+15.1%)
Beta0.56
S&P 52W Chg15.78%
Avg Vol (30d)394.01K
Avg Vol (10d)467.15K
Technical Indicators
RSI (14)47.6
MACD-0.1986
MACD Signal-0.1021
MACD Hist.-0.0966
BB Upper12.76 USD
BB Middle11.50 USD
BB Lower10.24 USD
BB Width21.95%
ATR (14)0.4644 USD
Vol Ratio (20d)1.71x